Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03115801
Recruitment Status : Recruiting
First Posted : April 14, 2017
Last Update Posted : August 13, 2018
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
The trial is open to patients who have metastatic renal cell carcinoma/urothelial (bladder) carcinoma with at least 2 measurable sites of disease. All eligible patients will be randomly assigned to immunotherapy(nivolumab/atezolizumab) versus immunotherapy (nivolumab/atezolizumab) plus radiotherapy, 10 Gy x3 (conformally or by intensity modulation radiation therapy/Image-guided radiation therapy (IMRT/IGRT) to maximally spare normal tissue), to one of their measurable lesions.

Condition or disease Intervention/treatment Phase
Metastatic Renal Cell Carcinoma Metastatic Urothelial Carcinoma Drug: Nivolumab Drug: Atezolizumab Radiation: Radiation & immunotherapy Phase 2

Detailed Description:
The trial is open to patients who have metastatic renal cell carcinoma/urothelial (bladder) carcinoma with at least 2 measurable sites of disease. All eligible patients will be randomly assigned to immunotherapy(nivolumab/atezolizumab) versus immunotherapy (nivolumab/atezolizumab) plus radiotherapy, 10 Gy x3 (conformally or by IMRT/IGRT to maximally spare normal tissue), to one of their measurable lesions. For patients assigned to the immunotherapy plus radiotherapy arm, immunotherapy treatment starts with the first radiotherapy fraction. Nivolumab will be given every 2 weeks for patients with metastatic renal cell cancer and atezolizumab will be given every 3 weeks for patients with metastatic urothelial cancer. Patients will be re-imaged at 9 week (year 1) or 12 week (years 2-3) intervals and evaluated for response (defined as an objective response of measurable metastatic sites outside the radiation field). This response will be evaluated with CT scans in non-irradiated measurable metastatic sites per RECIST version 1.1. Patients will continue to receive their respective immunotherapies for up to three years or until disease progression or until a dose limiting toxicity is reached.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Controlled Trial of Programmed Death -1/Programmed Death Ligand-1(PD-1/PDL-1) Axis Blockade Versus PD-1/PDL-1 Axis Blockade Plus Radiotherapy in Metastatic Genitourinary (Renal/Urothelial) Malignancies
Study Start Date : November 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2022


Arm Intervention/treatment
Active Comparator: Arm A - immunotherapy alone

Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.

Patients with Urothelial cancer will receive Atezolizumab on Days 1, 22, 43 and 64.

Drug: Nivolumab
Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
Other Name: Immunotherapy

Drug: Atezolizumab
Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Other Name: Tecentriq

Active Comparator: Arm B - Radiation & immunotherapy
Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
Drug: Nivolumab
Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
Other Name: Immunotherapy

Drug: Atezolizumab
Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Other Name: Tecentriq

Radiation: Radiation & immunotherapy
Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.




Primary Outcome Measures :
  1. best overall response rates of immunotherapy alone and of immunotherapy plus radiotherapy(to a single metastatic site). [ Time Frame: from 96 weeks ]
  2. difference in best overall response between the two groups, immunotherapy alone and of immunotherapy plus radiotherapy(to a single metastatic site). [ Time Frame: from 96 weeks ]

Secondary Outcome Measures :
  1. progression free survival [ Time Frame: from 96 weeks ]
  2. toxicities related to immunotherapy and immunotherapy plus radiotherapy treatment groups [ Time Frame: from 96 weeks ]
  3. overall survival [ Time Frame: from 96 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand and the willingness to sign a written informed consent document;
  2. Any prior therapy is permitted except prior therapy with PD1/PDL1 inhibitor.
  3. Histologic diagnosis of metastatic renal cell carcinoma or urothelial cancer;
  4. Patients must have at least 2 distinct measurable metastatic sites at least 1 cm or larger in their largest diameter per RECIST 1.1
  5. Patients must have adequate organ and marrow function as defined by initial laboratory tests.
  6. At least 2 weeks since last chemotherapy and 4 weeks since last immunotherapy treatment.
  7. Performance status Eastern cooperative oncology group (ECOG) 0-1
  8. Men and women, ages > 18 years of age.
  9. Life expectancy > 3 months
  10. Stable brain metastases for at least 4 weeks and not steroid dependent
  11. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the study in such a manner that the risk of pregnancy is minimized. Should a woman become pregnant or suspect she is pregnant while she is enrolled in this study, she should inform her treating physician immediately.

Exclusion Criteria:

  1. Patients having no lesions outside the field of radiation thus nullifying the ability to measure an abscopal effect;
  2. Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix;
  3. Autoimmune/auto inflammatory disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis];
  4. Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea;
  5. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of PD-1/PDL-1 blocking antibody).
  6. A history of prior treatment with PD-1/PDL-1blocking antibody;
  7. Patients who have had immunotherapy within 4 weeks prior to entering the study.
  8. Concomitant therapy with any of the following: interleukin -2 (IL-2), interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids;
  9. Patients undergoing therapy with other investigational agents or other chemotherapy agents;
  10. Women who:

    1. are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after cessation of study drug, or
    2. have a positive pregnancy test at baseline, or
    3. are pregnant or breastfeeding
  11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03115801


Contacts
Layout table for location contacts
Contact: Himanshu Nagar, M.D. 212-746-3704 hnagar@med.cornell.edu
Contact: Sharanya Chandrasekhar, M.S. 212-746-7277 shc2043@med.cornell.edu

Locations
Layout table for location information
United States, New York
Weill Cornell Medicine - New York Presbyterian Hospital Recruiting
New York, New York, United States, 10065
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Himanshu Nagar, M.D. Weill Cornell Medicine - New York Presbyterian Hospital

Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT03115801     History of Changes
Other Study ID Numbers: 1606017369
First Posted: April 14, 2017    Key Record Dates
Last Update Posted: August 13, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Renal Cell
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Nivolumab
Atezolizumab
Immunologic Factors
Antineoplastic Agents, Immunological
Antineoplastic Agents
Physiological Effects of Drugs